BHC at a glance
Bausch Health Companies Inc (BHC, SEC CIK 885590) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on July 29, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Bausch Health Companies Inc (BHC) reported revenue of $10.3 billion (up 6.7% from FY2024) and net income of $157.0 million. Diluted EPS was $0.42.
- As of June 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Bausch Health Companies Inc (BHC) shares worth $506.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Lenar Aimee J. on August 19, 2026 of 36,827 shares at $7.03 per share.
- In the last 90 days, BHC insiders reported 0 open-market purchases ($0) and 1 open-market sale ($259K) on Form 4, a net sale of $259K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $10.3B
- +6.7% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$259K
- 13F holders
- 23 funds
- $506.9M · +0 vs prior quarter
- Latest 10-Q
- Jul 30, 2026
- Quarterly report
SignalX for BHC
Don't miss the next BHC filing
- Alerts as it files. A push when BHC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BHC, by share count.
- Ask anything. An AI agent that reads every BHC filing and answers with sources.
BHC alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Paulson John | A | Sep 30, 2026 | 10,720 | $5.83 |
| WECHSLER AMY B | A | Sep 30, 2026 | 1,179 | $5.83 |
| LEUNG SANDRA | A | Sep 30, 2026 | 5,789 | $5.83 |
| Lenar Aimee J. | Sell | Aug 19, 2026 | 36,827 | $7.03 |
| Lenar Aimee J. | F | Jul 17, 2026 | 5,260 | $4.83 |
| Lenar Aimee J. | F | Jul 15, 2026 | 23,395 | $4.89 |
| LEE STEVEN HYOSIG | F | Jul 14, 2026 | 3,125 | $4.75 |
| Lee Frank D. | Sell | May 19, 2026 | 24,456 | $5.43 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $9.6B | $10.3B |
| Operating Income | - | $1.5B | $1.8B |
| Net Income | -$592.0M | -$46.0M | $157.0M |
| Op. Margin | - | 16.1% | 17.7% |
| Net Margin | - | -0.5% | 1.5% |
| Balance Sheet | |||
| Total Assets | $27.4B | $26.5B | $26.4B |
| Equity | - | -$1.3B | -$554.0M |
| ROE | - | 3.6% | -28.3% |
| Per Share | |||
| EPS | $-1.62 | $-0.13 | $0.42 |
| Cash Flow | |||
| Operating CF | - | $1.6B | $1.4B |
| CapEx | $215.0M | $337.0M | $397.0M |
Source: XBRL data in Bausch Health Companies Inc (BHC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate BHC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 23 | $506.9M |
| Q1 2026 | 23 | $532.0M |
| Q4 2025 | 24 | $738.0M |
| Q3 2025 | 24 | $630.0M |
| Q2 2025 | 23 | $604.0M |
| Q1 2025 | 21 | $580.3M |
| Q4 2024 | 18 | $750.4M |
| Q3 2024 | 15 | $661.6M |
- D.E. Shaw & Co+2.07M (+333%)
- Goldman Sachs Group+1.02M (+20%)
- Millennium Management+658.3K (+151%)
- Two Sigma Investments+557.4K (+35%)
- JPMorgan Chase & Co+427.0K (+94%)
- Dimensional Fund Advisors−363.7K (-10%)
- Renaissance Technologies LLC−251.2K (-16%)
- Citigroup−135.5K (-64%)
- Wells Fargo & Co−125.4K (-84%)
- Invesco Ltd−60.1K (-30%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 171 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BHC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | - | |
| 8-K | Jul 29, 2026 | - | - | - |
| 4 | Jul 20, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 15, 2026 | - | - | - |
| 8-K | Jul 1, 2026 | - | - | - |
| 4 | May 20, 2026 | - | - | |
| 8-K | May 19, 2026 | - | - | |
| 10-Q | Apr 30, 2026 | Mar 31, 2026 | - | |
| 8-K | Apr 29, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 8-K | Mar 2, 2026 | - | Analysis | - |
| 4 | Feb 27, 2026 | - | - | - |
| 4 | Feb 27, 2026 | - | - | - |
| 4 | Feb 27, 2026 | - | - | - |
| 10-K | Feb 19, 2026 | Dec 31, 2025 | - | |
| 8-K | Feb 18, 2026 | - | Analysis | |
| 4 | Feb 11, 2026 | - | - | |
| 4 | Feb 11, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
BHC SEC filings: frequently asked questions
Are BHC insiders buying or selling?
In the last 90 days, Bausch Health Companies Inc (BHC) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $258,894 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold BHC stock?
As of June 30, 2026, the largest Bausch Health Companies Inc (BHC) holders among the 13F filers tracked by SignalX were Paulson & Co ($361.2 million), Vanguard Capital Management LLC ($36.8 million), Goldman Sachs Group ($30.7 million), Dimensional Fund Advisors ($16.0 million), D.E. Shaw & Co ($13.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BHC's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Bausch Health Companies Inc (BHC) reported revenue of $10.3 billion (up 6.7% from FY2024) and net income of $157.0 million. Diluted EPS was $0.42. The figures come from the XBRL data in the 10-K.
What are the latest BHC SEC filings?
Bausch Health Companies Inc (BHC) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on July 29, 2026 and a Form 4 insider filing on October 2, 2026.
What is BHC's SEC CIK number?
Bausch Health Companies Inc (BHC)'s SEC Central Index Key (CIK) is 885590. EDGAR lists every BHC filing under that number.
Ask anything about BHC
The research agent reads BHC's filings, financials, insider trades and 13F holders, then answers with sources.